HLA antigens and bronchogenic carcinoma.
Twenty-one HLA-A and B antigens were determined in a study of 162 patients with lung cancer. Differences between antigen frequencies in cancer and control populations were determined by chi 2 analysis with Yates correction or Fisher's exact test. Cancer patients had a decreased frequency of the antigen HLA-B40 (pc = 0.003; relative risk = 0.21). In patients with differentiated types of the carcinoma and relatively better prognosis, decreased frequency of the antigen HLA-B40 was found (pc = 0.05; relative risk = 0.27). Our investigation was based on a thorough study of literary data.
Prazák
J
J
Institute of Hematology and Blood Transfusion, Prague, Czechoslovakia.
Mĕricka
O
O
D002283:Carcinoma, Bronchogenic / Q000276:immunology*; D002454:Cell Differentiation / Q000276:immunology; D006680:HLA Antigens / Q000032:analysis*; D015235:HLA-B Antigens; D059947:HLA-B40 Antigen; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology*; D011379:Prognosis; D012307:Risk Factors; D013601:T-Lymphocytes / Q000276:immunology*
D006680:HLA Antigens; D015235:HLA-B Antigens; D059947:HLA-B40 Antigen